BioCryst presents new real-world evidence showing high adherence and persistence rates with Orladeyo (berotralstat)

BioCryst Pharmaceuticals announced new real-world comparative research on the use of oral, once-daily Orladeyo (berotralstat) that found high rates of adherence and persistence for Orladeyo, similar to the rates observed with two other long-term prophylactic (LTP) therapies for HAE.

The company also announced new real-world evidence showing statistically significant and sustained HAE attack rate reductions after initiating Orladeyo in patients with HAE, regardless of their C1-inhibitor (C1-INH) deficiency status, and new findings from an HAE patient survey confirming patient preference for an oral LTP therapy.

Dr Donald S Fong, Chief Medical Officer of BioCryst, said: “These results build on previous research that highlights how the real-world effectiveness and convenience of our oral, once-daily prophylactic therapy are differentiators for patients. The strong adherence, persistence and preference for Orladeyo we report here provide further evidence that enables physicians to optimize individualized treatment recommendations for each of their patients. We continue to generate real-world evidence demonstrating that Orladeyo is a powerful, potentially life-changing treatment for many people with HAE.”

The data are being presented at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI), which is taking place in Boston from 24-28 October 2024.

(Source: BioCryst)